Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer

Tie-gang Liu,James Q Yin,Bo-yang Shang,Zhang Min,Hong-wei He,Jian-ming Jiang,Fang Chen,Yong-su Zhen,Rong-guang Shao
DOI: https://doi.org/10.1038/sj.cgt.7700753
IF: 5.854
2004-09-17
Cancer Gene Therapy
Abstract:RNA interference technology is a powerful tool for silencing endogenous or exogenous genes in mammalian cells. Here our results showed that hdm2-siRNA silenced its target mRNA specifically and effectively in human breast cancer cells, reduced tumor cell proliferation and induced apoptotic cell death. Other molecular features modified by hdm2-siRNA included decreased Bcl-2, NF-κB, survivin, Ras and Raf levels, elevated p53, p21, BRCA1, Bax, and caspase levels as well as altered expression of other genes. hdm2-siRNA also caused cell cycle arrest at G1 phases with reduction in cyclin and Cdk proteins. In addition, hdm2-siRNA displayed in vivo antitumor activity and increased therapeutic effectiveness of mitomycin in MCF-7 xenografts. Thus, hdm2-siRNA may be a promising gene-specific drug for the treatment of human breast cancer and other tumors.
oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?